BioNTech : Annual Report 2022

Consolidated Financial Statements BioNTech SE, Mainz as of December 31, 2022

Consolidated Statements of Profit or Loss

Years ended

2020
(in millions, except per share data)	Note
Revenues
Commercial revenues	6	€17,194.6	€18,874.0	€303.5
Research & development revenues	6	116.0	102.7	178.8
Total revenues	€17,310.6	€18,976.7	€482.3
Cost of sales	7.1	(2,995.0)	(2,911.5)	(59.3)
Research and development expenses	7.2	(1,537.0)	(949.2)	(645.0)
Sales and marketing expenses	7.3	(59.5)	(50.4)	(14.5)
General and administrative expenses	7.4	(484.7)	(285.8)	(94.0)
Other operating expenses	7.5	(407.0)	(94.4)	(2.4)
Other operating income	7.6	815.3	598.4	250.5
Operating income / (loss)	€12,642.7	€15,283.8	€(82.4)
Finance income	7.7	330.3	67.7	1.6
Finance expenses	7.8	(18.9)	(305.1)	(65.0)
Profit / (loss) before tax	€12,954.1	€15,046.4	€(145.8)
Income taxes	8	(3,519.7)	(4,753.9)	161.0
Profit for the period	€9,434.4	€10,292.5	€15.2
Earnings per share
Basic profit for the period per share	€38.78	€42.18	€0.06
Diluted profit for the period per share	€37.77	€39.63	€0.06

December 31, 2022 2021

The accompanying notes form an integral part of these consolidated financial statements.

Consolidated Statements of Comprehensive Income

Years ended December 31,
(in millions)	Note	2022	2021	2020
Profit for the period	€9,434.4	€10,292.5	€15.2
Other comprehensive income
Other comprehensive income that may be reclassified to profit or loss in subsequent periods, net of tax Exchange differences on translation of foreign operations
11.2	8.4	(11.1)
Net other comprehensive income / (loss) that may be reclassified to profit or loss in subsequent periods	€11.2	€8.4	€(11.1)
Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods, net of tax
Net gain on equity instruments designated at fair value through other comprehensive income Remeasurement income / (loss) on defined benefit plans	10.5	-	-
0.6	0.3	(0.3)
Net other comprehensive income / (loss) that will not be reclassified to profit or loss in subsequent periods	€11.1	€0.3	€(0.3)
Other comprehensive income / (loss) for the period, net of tax	€22.3	€8.7	€(11.4)
Comprehensive income for the period, net of tax	€9,456.7	€10,301.2	€3.8

The accompanying notes form an integral part of these consolidated financial statements.

Consolidated Statements of Financial Position

December 31,	December 31,
(in millions)	2022	2021
Assets	Note
Non-current assets
Intangible assets	11	€219.7	€202.4
Property, plant and equipment	10	609.2	322.5
Right-of-use assets	19	211.9	197.9
Other financial assets	12	80.2	21.3
Other non-financial assets	14	6.5	14.4
Deferred tax assets	8	229.6	-
Total non-current assets	€1,357.1	€758.5
Current assets
Inventories	13	439.6	502.5
Trade and other receivables	12	7,145.6	12,381.7
Other financial assets	12	189.4	381.6
Other non-financial assets	14	271.9	113.4
Income tax assets	8	0.4	0.4
Cash and cash equivalents	12	13,875.1	1,692.7
Total current assets	€21,922.0	€15,072.3
Total assets	€23,279.1	€15,830.8
Equity and liabilities
Equity
Share capital	15	248.6	246.3
Capital reserve	15	1,828.2	1,674.4
Treasury shares	15	(5.3)	(3.8)
Retained earnings	18,833.0	9,882.9
Other reserves	16	(848.9)	93.9
Total equity	€20,055.6	€11,893.7
Non-current liabilities
Lease liabilities, loans and borrowings	12	176.2	171.6
Other financial liabilities	12	6.1	6.1
Income tax liabilities	8	10.4	4.4
Provisions	17	8.6	184.9
Contract liabilities	6	48.4	9.0
Other non-financial liabilities	18	17.0	12.8
Deferred tax liabilities	8	6.2	66.7
Total non-current liabilities	€272.9	€455.5
Current liabilities
Lease liabilities, loans and borrowings	12	36.0	129.9
Trade payables	12	204.1	160.0
Other financial liabilities	12	785.1	1,190.4
Refund liabilities	6	24.4	90.0
Income tax liabilities	8	595.9	1,568.9
Provisions	17	367.2	110.2
Contract liabilities	6	77.1	186.1
Other non-financial liabilities	18	860.8	46.1
Total current liabilities	€2,950.6	€3,481.6
Total liabilities	€3,223.5	€3,937.1
Total equity and liabilities	€23,279.1	€15,830.8

The accompanying notes form an integral part of these consolidated financial statements.

Table of Contents

Consolidated Statements of Changes in Stockholders' Equity

(in millions)	Note	Share capital	Capital reserve	Treasury shares	Retained earnings	Other reserves (1)	Total equity
As of January 1, 2020	€232.3	€686.7	€(5.5)	€(424.8)	€4.8	€493.5
Profit for the period	-	-	-	15.2	-	€15.2
Other comprehensive loss	-	-	-	-	(11.4)	€(11.4)
Total comprehensive profit / (loss)	€-	€-	€-	€15.2	€(11.4)	€3.8
Issuance of share capital	14.0	861.0	0.7	-	-	€875.7
Transaction costs Share-based payments	17	- -	(33.2) -	- -	- -	- 32.0	€(33.2) €32.0
As of December 31, 2020	€246.3	€1,514.5	€(4.8)	€(409.6)	€25.4	€1,371.8
Profit for the period	-	-	-	10,292.5	-	€10,292.5
Other comprehensive income	-	-	-	-	8.7	€8.7
Total comprehensive income	-	-	-	10,292.5	8.7	€10,301.2
Issuance of treasury shares	16	-	162.6	1.0	-	-	€163.6
Transaction costs Share-based payments	17	- -	(2.7) -	- -	- -	- 59.8	€(2.7) €59.8
As of December 31, 2021	€246.3	€1,674.4	€(3.8)	€9,882.9	€93.9	€11,893.7
Profit for the period	-	-	-	9,434.4	-	€9,434.4
Other comprehensive income	-	-	-	-	22.3	€22.3
Total comprehensive income	€-	€-	€-	€9,434.4	€22.3	€9,456.7
Issuance of share capital	15	0.5	67.1	-	-	-	€67.6
Redemption of convertible note Share repurchase program Transaction costs Dividends Share-based payments Current and deferred taxes	12 15 15 16 8	1.8 - - - - -	233.2 (979.5) (0.1) - 833.1 -	- (6.9) - - 5.4 -	- - - (484.3) - -	- - - - (1,519.8) 554.7	€235.0 €(986.4) €(0.1) €(484.3) €(681.3) €554.7
As of December 31, 2022	€248.6	€1,828.2	€(5.3)	€18,833.0	€(848.9)	€20,055.6

(1) Includes foreign currency translation reserve which was presented separately in prior periods.

4